FDA issues warning letter over Cymbalta physician promo
The FDA has issued Eli Lilly a warning letter over effectiveness claims the company made in a 2005 promotional mailer to physicians for its blockbuster antidepressant/nerve pain treatment Cymbalta.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.